Friday, 17 Nov 2017

You are here

Top 16 Drugs in Rheumatology 2016

Using data compiled from annual reports, SEC filings, press releases, company websites, recently released sales figures show that in 2016, 11 of the top 16 rheumatology drugs demonstrated blockbuster sales (>$1 billion per annum).  Highlights from this report include:

  • TNF inhibitors – the big three TNFi (ADA, ETN, INF) lead the way with $33.7 billion in 2016.  Humira continued as the worldwide leader in sales $16.1 billion.  Sales of all 5 TNFi totaled $37.9 billion.  While Humira growth (15%) continues, Enbrel has flattened (2%) and Remicade has declined (-2%).
  • Greatest growth from 2015 to 2016 was Cosentyx (332% to $1.1 billion in 2016), Otezla (116% to $1 billion) and Xeljanz (77% to $927 million).
  • Greatest losses were seen for NSAID market, with -12% drop for Celebrex, -4% drop for Arcoxia (Cox-2 inhibitor sold outside the USA) and a -2% drop for aspirin.
  • Psoriatic arthritis therapeutic market was hot with substantial growth by Cosentyx (332%), Otezla (116%) and Stelara (31%), in addition to TNF inhibitor growth.

TOP 16 RHEUMATOLOGY DRUGS – 2016 SALES

 

Brand

Generic

2015 Sales*

2016 Sales*

Growth Rate

1

Humira

Adalimumab

14012

16078

15%

2

Enbrel

Etanercept

8697

8874

2%

3

Remicade

Infliximab

8791

8789

-2%

4

Rituxan

Rituximab

5584

5765

3%

5

Stelara

Ustekinumab

2474

3232

31%

6

Simponi

Golimumab

2133

2719

27%

7

Orencia

Abatacept

1957

.2368

21%

8

Actemra

Tocilizumab

1432

1697

19%

9

Cimzia

Certolizumab

1191

1438

21%

10

Cosentyx

Secukinumab

261

1128

332%

11

Otezla

Apremilast

472

1017

116%

12

Xeljanz

Tofacitinib

523

927

77%

13

Celebrex

Celcoxib

830

733

-12%

14

Aspirin

Aspirin

525

513

-2%

15

Arcoxia

Etoricoxib

471

450

-4%

16

Ilaris

Canakinumab

236

283

20%

* Worldwide sales expressed millions (USD)

Add new comment

More Like This

ACR 2017 - Day 1 Highlights

Curtis and colleagues presented a plenary session that analyzed the duration of drug holidays and the risk of subsequent fractures (FX) in women starting bisphosphonates (BP). They looked at 156,236 women taking BP for 3 years (median 2.1 yrs.) and then discontinuing BP.  20% stopped BP for > 6 mos. and 12.7% restarted BP and 11% died. For those off BP for >2 yrs. there was a 40% increased risk of Hip Fx.

The Greatest Rheumatologist - Part I

Who is the greatest rheumatologist? What makes for a great rheum? Is it clinical acumen, scientific achievement, educational prowess or years of unrivaled service or mentoring? Rheumatologists are quite opinionated on this subject and very nostalgic about their mentors and leaders. When I’ve posed this question in small groups, it’s plain to see how moved they become when discussing mentors or peers who influenced them. Thus, I posed this question to many of our leaders and mentors: who do you think of as the greatest rheumatologist?

Rheumatologists are Slow to Change DMARDs

The paradigm of rheumatoid arthritis (RA) therapy mandates early diagnosis and aggressive treatment.  Yet a recent cohort study has shown that RA patients with moderate to high disease activity (MHDAS) were met with infrequent DMARD adjustments; with median time to DMARD adjustment being 5 months and median time to low disease activity (LDAS) was roughly 10 months. 

Novel Gel Drug Delivery Developed for Rheumatoid Arthritis

Scientists at the Institute for Basic Science have invented a hydrogel capable of delivering drug at sites of inflammation in disorders such as rheumatoid arthritis. Published in Advanced Materials, this jelly-like material could be used to absorb extra fluids in swelling joints and release drugs wherever nitric oxide is produced in abundance.

2016 EULAR Guidelines on RA Management

The management of rheumatoid arthritis (RA) has evolved significantly with time.  Nevertheless, there are still some uncertainties - such as when, what and which biologic or novel therapy should be used.